KLK3 and prostate cancer: Is the addition of docetaxel to standard of care (SOC) therapy with radiation and testosterone suppression or radical prostatectomy associated with decreased risk of prostate cancer–specific and all-cause deaths in patients with high-grade, nonmetastatic prostate cancer with low prostate-specific antigen levels?